

U.S.S.N: 10/027,982

Supplemental Response to Advisory Action dated September 2, 2003


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (Canceled).

Claim 7 (Currently amended). A compound of formula I



diastereomers, enantiomers or salts thereof

where

R₁ is hydrogen or R₆;

R_{1ad} and R_{1ac} are independently hydrogen, R₆ or -OR₆;

R_{1ad} is hydrogen;

one of R₂ or R₃ is hydrogen or alkyl and the other R₂ or R₃ is -Z₄-R_{6a}, where: Z₄ is -Z₄₁-C(O)-Z₄₂- and R_{6a} is phenyl substituted with Z₃;

R₆ is alkyl;

R₁, R_{1ad}, R_{1ac} and R_{1ab} are independently

- (1) — hydrogen or R₆;
- (2) — OH or -OR₆;
- (3) — SH or -SR₆;
- (4) — C(O)_qH, C(O)_qR₆, or -O-C(O)_qR₆, where q is 1 or 2;
- (5) — SO₂H or -S(O)_qR₆;

U.S.S.N: 10/027,982

Supplemental Response to Advisory Action dated September 2, 2003

(6) — halo;

(7) — cyano;

(8) — nitro;

(9) — $Z_4-NR_{6i}R_{8j}$;(10) — $Z_4-N(R_9)-Z_5-NR_{10}R_{11}$;(11) — $Z_4-N(R_{12})-Z_3-R_6$; or(12) — $P(O)(OR_6)_2$; R_2 and R_3 are each independently H, Z_4-R_{6is} or $Z_4-NR_{7d}R_{8d}$;

R_6 , R_{6is} and R_{6d} are independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclo, or heterocycloalkyl, each of which is unsubstituted or substituted with Z_1 , Z_2 and one or more groups Z_3 ;

 R_{7d} , R_{8d} , R_9 , R_{10} , R_{11} and R_{12} (1) are each independently hydrogen, or Z_4R_{6is} ; or

(2) R_9 and R_{10} may together be alkylene, alkenylene, or heteroalkylene, completing a 3- to 8-membered saturated or unsaturated ring with the nitrogen atom to which they are attached, which ring is unsubstituted or substituted with Z_4 , Z_2 and one or more groups Z_3 ; or

(3) any two of R_9 , R_{10} and R_{11} may together be alkylene, alkenylene or heteroalkylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more Z_1 , Z_2 and Z_3 ;

 X_2 is CZ_{3d} , NZ_{3d} , O or S;

Z_{3a} is $-C(O)_qZ_{6a}$, where q is 1 H, hydroxy, optionally substituted alkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted aralkyl, OZ_6 , $C(O)_dH$, $-C(O)_qZ_{6is}-Z_4-NZ_7Z_8$, or $Z_4-N(Z_{10})-Z_3-Z_6$;

n is 1 to 3 2;

m is zero to 2 1;

 Z_1 and Z_2 are hydrogen; Z_3 is $-Z_4-NZ_7Z_8$, where Z_4 is alkyl; Z_1 , Z_2 and Z_3 are each independently(1) — hydrogen or Z_6 ;

U.S.S.N: 10/027,982

Supplemental Response to Advisory Action dated September 2, 2003

(2) — OH or OZ_{67} (2) — SH or SZ_{67} (4) — $\text{C}(\text{O})_q\text{H}_7$, $\text{C}(\text{O})_q\text{Z}_{67}$, or $\text{O}-\text{C}(\text{O})_q\text{Z}_{67}$, where q is 1 or 2,(5) — SO_2H_7 , $\text{S}(\text{O})_q\text{Z}_{67}$, or $\text{S}(\text{O})_q\text{N}(\text{Z}_5)\text{Z}_{67}$

(6) — halo,

(7) — cyano,

(8) — nitro,

(9) — $\text{Z}_4\text{-NZ}_{77}\text{Z}_{87}$ (10) — $\text{Z}_4\text{-N}(\text{Z}_9)\text{-Z}_5\text{-NZ}_{77}\text{Z}_{87}$ (11) — $\text{Z}_4\text{-N}(\text{Z}_{10})\text{-Z}_5\text{-Z}_{67}$ (12) — $\text{Z}_4\text{-N}(\text{Z}_{10})\text{-Z}_5\text{-H}_7$

(13) — oxo,

(14) — any two of Z_4 , Z_5 , and Z_6 on a given substituent may together be alkylene or alkenylene completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached; or(15) — any two of Z_4 , Z_5 , and Z_6 on a given substituent may together be $-\text{O}-(\text{CH}_2)_q-\text{O}-$; Z_4 and Z_5 are each independently

(1) — a single bond,

(2) — $\text{Z}_{11}\text{-S}(\text{O})_q\text{-Z}_{12}$,(3) — $\text{Z}_{11}\text{-C}(\text{O})\text{-Z}_{12}$,(4) — $\text{Z}_{11}\text{-C}(\text{S})\text{-Z}_{12}$,(5) — $\text{Z}_{11}\text{-O}\text{-Z}_{12}$,(6) — $\text{Z}_{11}\text{-S}\text{-Z}_{12}$,(7) — $\text{Z}_{11}\text{-O}\text{-C}(\text{O})\text{-Z}_{12}$,(8) — $\text{Z}_{11}\text{-C}(\text{O})\text{-O}\text{-Z}_{12}$; or

(9) — alkyl

 Z_8 and Z_{62} is alkyl; are independently

(i) — alkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, alkylaryl, cycloalkylaryl, heterocycle, or heterocycloalkyl;

U.S.S.N: 10/027,982

Supplemental Response to Advisory Action dated September 2, 2003

(ii) ~~a group (i) which is itself substituted by one or more of the same or different groups (i);~~
or

(iii) ~~a group (i) or (ii) which is independently substituted by one or more of the groups (2) to (15) of the definition of Z_{6a};~~

Z₇ and Z₈ are each independently hydrogen or -Z₄-Z_{6a}, where Z₄ is a single bond;

Z₇, Z₈, Z₉ and Z₁₀

(1) are each independently hydrogen or -Z₄-Z_{6a};

(2) Z₇ and Z₈ may together be alkylene, alkenylene, or heteroalkylene completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more Z₁, Z₂ and Z₃; or

(3) Z₇ or Z₈, together with Z₉, may be alkylene, alkenylene, or heteroalkylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more Z₁, Z₂ and Z₃;

Z₁₁ and Z₁₂ are each independently a single bond.


(1) a single bond;

(2) alkylene;

(3) alkenylene; or

(4) alkenylene;

Claim 8 (Previously presented). A compound of claim 7 having the formula



Claim 9 (Currently amended). A compound of claim 8 where

R₂ is hydrogen or alkyl; and

R₃ is -Z₄R_{6a}, where: Z₄ is -C(O)- and R_{6a} is phenyl substituted with Z₃.

U.S.S.N: 10/027,982

Supplemental Response to Advisory Action dated September 2, 2003

(a) Z_4 is a single bond and R_{4a} is heteroaryl optionally substituted with one or more Z_1 , Z_2 , or Z_3 ;

(b) Z_4 is $-C(O)-$ and R_{4a} is

(1) aryl optionally substituted with one or more Z_1 , Z_2 , or Z_3 ;

(2) alkyl optionally substituted with one or more Z_1 , Z_2 , or Z_3 ;

(3) cycloalkyl optionally substituted with one or more Z_1 , Z_2 , or Z_3 ; or


(4) heterocyclo optionally substituted with one or more Z_1 , Z_2 , or Z_3 ; or

(c) Z_4 is $-C(O)-O-$ and R_{4a} is alkyl, cycloalkyl, aryl or aralkyl, any of which may be optionally substituted with one or more Z_1 , Z_2 or Z_3 .

Claim 10 (Currently amended). A compound of claim 9 wherein R_{1ab} [[,]] and R_{1ac} and R_{1ad} are independently H[[,]] or alkyl, hydroxy, nitro, halo, $-OR_6$, $-NR_4R_5$, $-C(O)_qH$ or $-C(O)_qR_6$.

Claim 11 (Original). A compound of claim 10 wherein R_{1ab} and R_{1ac} are independently alkyl.

Claim 12 (Currently amended). A compound of claim 8 having the following formula



where one of R_{1ab} [[,]] and R_{1ac} and R_{1ad} is H and the other is alkyl or $-OR_6$ two are independently alkyl, hydroxy, nitro, halo, $-OR_6$, $-NR_4R_5$, $-C(O)_qH$, or $-C(O)_qR_6$.

Claim 13 (Currently amended). A compound of claim 12 wherein one of R_{1ab} [[,]] and R_{1ac} and R_{1ad} is H and the other is two are independently alkyl or $-OR_6$.

Claim 14 (Previously presented). A compound of claim 13 wherein R_{1ac} is H.

U.S.S.N: 10/027,982

Supplemental Response to Advisory Action dated September 2, 2003

Claim 15 (Canceled).

Claim 16 (Canceled)

Claim 17 (Previously presented). A pharmaceutical composition comprising at least one compound of claim 7 and a pharmaceutically acceptable vehicle or carrier therefor.

Claim 18 (Original). A pharmaceutical composition of claim 17 further comprising at least one additional therapeutic agent selected from anti-inflammatory agents, anti-proliferative agents, anti-cancer agents or anti-cytotoxic agents.

Claim 19 (Original). A pharmaceutical composition of claim 18 wherein the additional therapeutic agents are selected from steroids, mycophenolate mofetil, LTD₄ inhibitors, CTLA4-Ig, LEA-29Y, phosphodiesterase inhibitors, antihistamines, or p³⁸ MAPK inhibitors.

Claims 20 – 22 (Canceled).

Claims 23-25 (Not entered).